TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2972540

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 75 micrograms (Group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 75 micrograms with adrenaline 75 micrograms (Group 2)
Number of subjects: 20
Study: 31707049

Group type: EXPERIMENTAL
Intervention: Zataria multiflora 5 mg/kg/day (Z5)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Zataria multiflora 10 mg/kg/day (Z10)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 35
Study: 31242139

Group type: EXPERIMENTAL
Intervention: Contrast water therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined cold water immersion and active recovery
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Active recovery
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study: 28233105

Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Silk sutures
Number of subjects: 1147
Study: 25217988

Group type: EXPERIMENTAL
Intervention: Sling immobilization
Number of subjects: 21

Group type: COMPARATOR
Intervention: No sling
Number of subjects: 21
Study: 21246277

Group type: EXPERIMENTAL
Intervention: Writing narratives about traumatic or stressful life events (prayers to God)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Writing narratives about traumatic or stressful life events (targeted at a person of their choice)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Writing narratives about traumatic or stressful life events (not targeted at anyone)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group writing about mundane experiences
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Trauma writing
Number of subjects: 155
Study: 21309657

Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily)
Number of subjects: 5599

Group type: COMPARATOR
Intervention: Aspirin (81 to 324 mg per day)
Number of subjects: 5599

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5599

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5599
Study: 18587635

Group type: EXPERIMENTAL
Intervention: Valid study
Number of subjects: 248

Group type: COMPARATOR
Intervention: Missing control group
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Internal validity (valid vs. missing control group)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Ecological validity (high vs. low)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Expert evidence quality, expert credibility, and plaintiff credibility
Number of subjects: 248
Study: 16958285

Group type: EXPERIMENTAL
Intervention: R + PBNT + CRR
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PBNT + CRR + R
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: R + CSEB + CRR
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CSEB + CRR + R
Number of subjects: 30

Group type: COMPARATOR
Intervention: PBNT + CRR
Number of subjects: 30

Group type: COMPARATOR
Intervention: CSEB + CRR
Number of subjects: 30
Study: 15304585

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 3706

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3706
Study: 10890285

Group type: EXPERIMENTAL
Intervention: Telephone survey (DAT group)
Number of subjects: 126966

Group type: COMPARATOR
Intervention: Mail survey (AT group)
Number of subjects: 126966

Group type: COMPARATOR
Intervention: AT group (compared to DAT group)
Number of subjects: 126966

Group type: EXPERIMENTAL
Intervention: Both groups (DAT and AT)
Number of subjects: 126966

Group type: EXPERIMENTAL
Intervention: Telephone survey (both groups)
Number of subjects: 126966

Group type: COMPARATOR
Intervention: AT group (late response)
Number of subjects: 126966
Study: 8677870

Group type: EXPERIMENTAL
Intervention: Atenolol and nifedipine
Number of subjects: 235

Group type: COMPARATOR
Intervention: Diltiazem and isosorbide dinitrate
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 235
Study: 2064065

Group type: EXPERIMENTAL
Intervention: Lumbar epidural morphine 5 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lumbar epidural nalbuphine 10 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lumbar epidural nalbuphine 20 mg
Number of subjects: 15
Study: 6321426

Group type: EXPERIMENTAL
Intervention: Imipenem with cilastatin, 500 mg/500 mg iv tid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cefotaxime, 2 g iv tid
Number of subjects: 40
Study: 30564847

Group type: EXPERIMENTAL
Intervention: Paravertebral block (Pv, n=20) with 20 ml 0.25% bupivacaine at the level of T8-T9
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peritubal infiltration (Pi, n=20) with 20 ml 0.25% bupivacaine along the nephrostomy tube
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (C, n=20): no intervention
Number of subjects: 60
Study: 30339623

Group type: EXPERIMENTAL
Intervention: Patch repair (PROCEED Ventral Patch)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Polypropylene mesh repair
Number of subjects: 352
Study: 28472642

Group type: EXPERIMENTAL
Intervention: Seasoned vegetables (SS)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Steamed vegetables (ST)
Number of subjects: 335
Study: 25259404

Group type: EXPERIMENTAL
Intervention: Inferior conjunctival autografting (ICA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Superior conjunctival autografting (SCA)
Number of subjects: 80
Study: 23380218

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg/d
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: Fluticasone 250 μg twice daily
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1019
Study: 21211684

Group type: EXPERIMENTAL
Intervention: Years of education >16 years
Number of subjects: 11326

Group type: COMPARATOR
Intervention: Years of education <8 years
Number of subjects: 11326

Group type: EXPERIMENTAL
Intervention: Increase in years of education (per year)
Number of subjects: 11326
Study: 19230906

Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Number of subjects: 140

Group type: COMPARATOR
Intervention: IFD CPAP
Number of subjects: 140
Study: 16563995

Group type: EXPERIMENTAL
Intervention: PHDRB (4 Gy b.i.d. x 8 for R0 resections and 4 Gy b.i.d. x 10 for R1 resections)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PHDRB
Number of subjects: 25
Study: 15619331

Group type: EXPERIMENTAL
Intervention: Tailor-made treatment program addressing biopsychosocial factors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 10620554

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rTPA) 2 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Heparin 2,000 IU
Number of subjects: 12
Study: 8648870

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 536

Group type: COMPARATOR
Intervention: Tricyclic antidepressants (imipramine or desipramine)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Fluoxetine, Tricyclic antidepressants
Number of subjects: 536
Study: 1335647

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (720 ELISA units)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 micrograms)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of hepatitis A and B vaccines
Number of subjects: 165
Study: 6100260

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg dose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no drug administration)
Number of subjects: 13
Study: 3033966

Group type: EXPERIMENTAL
Intervention: Oral morphine (30 mg slow-release preparation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg bolus iv)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg iv bolus followed by continuous infusion of 6 mg over 75 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (for both morphine and naloxone protocols)
Number of subjects: 20
Study: 29890806

Group type: EXPERIMENTAL
Intervention: Acupotomy stress position percutaneous dynamic release
Number of subjects: 160

Group type: COMPARATOR
Intervention: Simple joint loosening according to Maitland technique (control group)
Number of subjects: 160
Study: 27590255

Group type: EXPERIMENTAL
Intervention: Individual feedback on step-counts
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Social feedback comparing step-counts against others
Number of subjects: 165

Group type: COMPARATOR
Intervention: No feedback (control)
Number of subjects: 165
Study: 25622666

Group type: EXPERIMENTAL
Intervention: 270 mgI/ml low concentrations of contrast agents and spectral CT imaging (Group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 350 mgI/ml high concentrations of contrast agents and 120 kVp scan (Group B)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Optimal keV images (Group C)
Number of subjects: 160
Study: 23615823

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham vaccination
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High cardiorespiratory fitness group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low cardiorespiratory fitness group
Number of subjects: 40
Study: 20215126

Group type: EXPERIMENTAL
Intervention: CFE ablation alone (n = 34)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PVI ablation alone (n = 32)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PVI + CFE ablation (n = 34)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 100
Study: 18721899

Group type: EXPERIMENTAL
Intervention: High-dose fish oil (9600 mg of fish oil/day, 2880 mg of n-3 fatty acids)
Number of subjects: 11
Study: 16943516

Group type: EXPERIMENTAL
Intervention: Method 1 (highest interexaminer reliability)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Method 2 (at least one test result abnormal)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Method 3 (all test results abnormal)
Number of subjects: 24
Study: 14576512

Group type: EXPERIMENTAL
Intervention: hANP (initial dose: 0.025 microg/kg/min, maximum dose: 0.035 +/- 0.019 microg/kg/min)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: hANP
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (nicardipine hydrochloride; 4.41 +/- 1.68 mg/h)
Number of subjects: 50
Study: 11109234

Group type: EXPERIMENTAL
Intervention: Arousal (D) cluster of symptoms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiological indices of arousal and reactivity
Number of subjects: 0
Study: 8677571

Group type: EXPERIMENTAL
Intervention: Neoadjuvant MVAC chemotherapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Adjuvant MVAC chemotherapy
Number of subjects: 95
Study: 2072368

Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg twice daily
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg once daily
Number of subjects: 115
Study: 6353623

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 60
Study: 30871785

Group type: EXPERIMENTAL
Intervention: Self‐observation of the Body (SoB) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mental Monitoring (MM) training
Number of subjects: 0
Study: 29189967

Group type: EXPERIMENTAL
Intervention: Standardized nursing intervention consisting of an in-person supportive care assessment with ongoing support to meet identified needs, including linkage to community services.
Number of subjects: 193

Group type: COMPARATOR
Intervention: Usual care practices (Control group).
Number of subjects: 193
Study: 27059799

Group type: EXPERIMENTAL
Intervention: Clazakizumab 100 mg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Clazakizumab 25 mg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Clazakizumab 200 mg
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Clazakizumab (all doses)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Clazakizumab
Number of subjects: 165
Study: 24697794

Group type: EXPERIMENTAL
Intervention: Full dental arch (RPDs with artificial molars)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Shortened dental arch (RPDs lacking artificial molars)
Number of subjects: 11
Study: 22507276

Group type: EXPERIMENTAL
Intervention: Two-strain combination probiotic (Lactobacillus acidophilus and Bifidobacterium bifidum) given twice a day for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo given twice a day for 3 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Two-strain combination probiotic
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 20562586

Group type: EXPERIMENTAL
Intervention: T. vaginalis infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV infection
Number of subjects: 0
Study: 18628618

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day) for 14 days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: L-arginine (500 microM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: L-N(5)-(I-iminoethyl)ornithine (NOS inhibitor)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Platelet eNOS mRNA and protein levels
Number of subjects: 22
Study: 15769245

Group type: EXPERIMENTAL
Intervention: Advantage in BATNA (Better Alternative to a Negotiated Agreement)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advantage in contributions
Number of subjects: 0
Study: 11315826

Group type: EXPERIMENTAL
Intervention: Diuretic (chlorthalidone)
Number of subjects: 15297

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (amlodipine)
Number of subjects: 15297

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril)
Number of subjects: 15297

Group type: EXPERIMENTAL
Intervention: Alpha-adrenergic blocker (doxazosin)
Number of subjects: 15297
Study: 9326656

Group type: EXPERIMENTAL
Intervention: Oral pyrimidine nucleoside or nucleotide compounds
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 7868871

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 13
Study: 3061422

Group type: EXPERIMENTAL
Intervention: Midazolam alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diazepam with pethidine
Number of subjects: 100
Study: 30528654

Group type: EXPERIMENTAL
Intervention: Multiple sessions of multisite transcranial random noise stimulation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Single session of multisite transcranial random noise stimulation
Number of subjects: 29
Study: 28302288

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2824

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2824
Study: 25692257

Group type: EXPERIMENTAL
Intervention: Syndecan-1 (S1) levels measured at admission and after one day
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan heparan sulfate levels measured at admission and after one day
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Admission S1 levels in survivors vs non-survivors at 30 days
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: S1 as an independent predictor of 30-day mortality
Number of subjects: 184
Study: 23973946

Group type: EXPERIMENTAL
Intervention: Novel imaging group (Allura Clarity)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Reference group (Allura Xper)
Number of subjects: 136
Study: 21356082

Group type: EXPERIMENTAL
Intervention: Aerobic physical exercise
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Micronutrients capsule (zinc 30 mg, selenium 70 μg, vitamin A 400 μg, alpha-tocopherol 30 mg, vitamin C 200 mg, niacin 100 mg)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Combined interventions (micronutrients and aerobic exercise)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual prenatal care and placebo (maltodextrin)
Number of subjects: 320
Study: 19245076

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment in a hyperbaric chamber
Number of subjects: 30
Study: 17978325

Group type: EXPERIMENTAL
Intervention: Real rTMS stimulation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 127
Study: 15172903

Group type: EXPERIMENTAL
Intervention: Multi‐institutional quality improvement collaborative (the 'Breakthrough Series')
Number of subjects: 9986

Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 9986
Study: 11672947

Group type: EXPERIMENTAL
Intervention: Ecstasy use
Number of subjects: 3274

Group type: EXPERIMENTAL
Intervention: Polydrug use
Number of subjects: 3274

Group type: EXPERIMENTAL
Intervention: Self-reported symptoms
Number of subjects: 3274

Group type: EXPERIMENTAL
Intervention: Social distribution of drug use
Number of subjects: 3274
Study: 9039532

Group type: EXPERIMENTAL
Intervention: High-dose clarithromycin (1,000 mg or 750 mg b.i.d.)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low-dose clarithromycin (1,000 mg or 750 mg q.d.)
Number of subjects: 45
Study: 8176095

Group type: EXPERIMENTAL
Intervention: 100 mg of atenolol once a day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 200 mg of controlled-release metoprolol once a day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo once a day
Number of subjects: 18
Study: 3283918

Group type: EXPERIMENTAL
Intervention: Al-Mg antacids (one tablet four times daily; acid-neutralizing capacity, 120 mmol/day) + pirenzepine (50 mg twice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Al-Mg antacids (one tablet four times daily; acid-neutralizing capacity, 120 mmol/day) + pirenzepine placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antacid placebo + pirenzepine (50 mg twice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antacid placebo + pirenzepine placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg twice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antacid placebo
Number of subjects: 100
Study: 29468315

Group type: EXPERIMENTAL
Intervention: SP base osteotomy
Number of subjects: 97

Group type: COMPARATOR
Intervention: SP splitting osteotomy
Number of subjects: 97
Study: 28069089

Group type: EXPERIMENTAL
Intervention: Test meal with 19-mg (all-E)-LYC from tomato paste
Number of subjects: 10

Group type: COMPARATOR
Intervention: Test meal with 19-mg (all-E)-LYC from tomato paste plus 500-mg calcium carbonate
Number of subjects: 10
Study: 25432920

Group type: EXPERIMENTAL
Intervention: Closed incubator system
Number of subjects: 364

Group type: COMPARATOR
Intervention: Conventional incubator system (control)
Number of subjects: 364
Study: 23834402

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 37
Study: 21756382

Group type: EXPERIMENTAL
Intervention: Burdizzo clamp ablation of the testes (CAT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Bilateral orchiectomy (BO)
Number of subjects: 19
Study: 19629060

Group type: EXPERIMENTAL
Intervention: Exercise (150 min/week of supervised gym‐ and home‐based moderate‐intensity aerobic exercise)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care (maintain current physical activity level)
Number of subjects: 75
Study: 16611682

Group type: EXPERIMENTAL
Intervention: Oral saline hydration (1 g/10 kg of body weight/day for 2 days before the procedure)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Intravenous saline hydration (0.9% saline at a rate of 15 ml/kg for 6 h before the procedure)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Intravenous saline hydration plus theophylline (5 mg/kg per os 1 h before the procedure)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Intravenous saline hydration plus furosemide (3 mg/kg intravenously just after the procedure)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 312
Study: 15478160

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (maximum 1,500 mg/day)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 11505880

Group type: EXPERIMENTAL
Intervention: High dose dexamethasone (100 mg stat, 16 mg every 6 hours for 48 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (equivalent volumes to dexamethasone)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High dose dexamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8564394

Group type: EXPERIMENTAL
Intervention: Dispersed pattern of presented stereotype inconsistent information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concentrated pattern of presented stereotype inconsistent information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiar groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfamiliar groups
Number of subjects: 0
Study: 2515634

Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine and dapsone)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 320955

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nonspecific therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 31
Study: 31034297

Group type: EXPERIMENTAL
Intervention: Judo training (1 hr session, biweekly for 4 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30
Study: 28497218

Group type: EXPERIMENTAL
Intervention: Integra Flowable Wound Matrix
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wet dressing
Number of subjects: 60
Study: 25349107

Group type: EXPERIMENTAL
Intervention: SPF 30 sunscreen plus antioxidant cocktail (grape seed extract, vitamin E, ubiquinone, vitamin C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SPF 30 sunscreen alone
Number of subjects: 30
Study: 24708480

Group type: EXPERIMENTAL
Intervention: Melatonin (50 mg infusion intra-operatively, 10 mg orally for the first three nights post-surgery)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 50
Study: 22285168

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg per day
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard chemotherapy (cisplatin 75 mg/m2 plus docetaxel 75 mg/m2 or gemcitabine 1250 mg/m2)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 174